达雷妥尤单抗在致敏肾移植中的应用:实验与临床的潜力及局限
该研究在致敏恒河猴模型中用达雷妥尤单抗(抗CD38单抗)联合普乐沙福降低供者特异性抗体并延长肾移植物存活,但抗体快速反弹并出现严重T细胞介导排斥。两例临床患者中观察到I类和II类供者特异性抗体显著下降并带来临床改善,支持进一步研究其作为脱敏或抗体介导排斥治疗策略的潜力。
要点
- 达雷妥尤单抗可显著降低致敏猴供者特异性抗体并延长肾移植物存活
- 但抗体快速反弹并伴严重T细胞介导排斥,提示单药局限
- 两例临床患者中抗体显著下降并临床改善,需进一步研究
核心结论
- 靶向CD38的达雷妥尤单抗在非人灵长类模型和两例移植临床病例中显著降低抗HLA抗体及抗HLA供者特异性抗体。
- 该结果支持将达雷妥尤单抗作为潜在治疗策略进行研究,但其用于抗体介导排斥和脱敏仍需进一步研究。
研究设计与样本
- 研究对8只经两次MHC错配供者皮肤移植致敏的恒河猴进行实验,其中4只接受达雷妥尤单抗联合普乐沙福脱敏治疗。
- 研究还治疗了两例移植临床患者:一例为合并心脏和肾脏移植且难治性抗体介导排斥的受者,另一例为高度致敏的心脏移植候选者。
主要发现
- 达雷妥尤单抗治疗组供者特异性抗体水平较未治疗对照组显著降低(降低57.9%对13%;P<0.05)。
- 达雷妥尤单抗治疗组肾移植物存活较对照组延长(28.0天对5.2天;P<0.01)。
- 所有受者均出现抗体快速反弹并伴严重T细胞介导排斥,供者特异性抗体下降未能维持。
- 两例临床患者中观察到I类和II类供者特异性抗体显著下降,并带来抗体介导排斥的临床改善和心脏移植物获取机会。
临床怎么用
- 达雷妥尤单抗可作为致敏移植受者脱敏或抗体介导排斥治疗的潜在策略,但需警惕抗体反弹和T细胞介导排斥。
- 临床使用时应密切监测供者特异性抗体水平和排斥反应,目前证据限于实验模型和个案,尚不能常规推荐。
局限性
- 非人灵长类模型样本量小(致敏猴共8只,治疗组4只),结果需谨慎解读。
- 临床部分仅两例患者,证据级别有限。
- 抗体下降不持久且出现严重T细胞介导排斥,提示单药方案局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Donor-specific antibodies are associated with increased risk of antibody-mediated rejection and decreased allograft survival. Therefore, reducing the risk of these antibodies remains a clinical need in transplantation. Plasma cells are a logical target of therapy given their critical role in antibody production. METHODS: To target plasma cells, we treated sensitized rhesus macaques with daratumumab (anti-CD38 mAb). Before transplant, we sensitized eight macaques with two sequential skin grafts from MHC-mismatched donors; four of them were also desensitized with daratumumab and plerixafor (anti-CXCR4). We also treated two patients with daratumumab in the context of transplant. RESULTS: The animals treated with daratumumab had significantly reduced donor-specific antibody levels compared with untreated controls (57.9% versus 13% reduction; P<0.05) and prolonged renal graft survival (28.0 days versus 5.2 days; P<0.01). However, the reduction in donor-specific antibodies was not maintained because all recipients demonstrated rapid rebound of antibodies, with profound T cell-mediated rejection. In the two clinical patients, a combined heart and kidney transplant recipient with refractory antibody-mediated rejection and a highly sensitized heart transplant candidate, we also observed a significant decrease in class 1 and 2 donor-specific antibodies that led to clinical improvement of antibody-mediated rejection and to heart graft access. CONCLUSIONS: Targeting CD38 with daratumumab significantly reduced anti-HLA antibodies and anti-HLA donor-specific antibodies in a nonhuman primate model and in two transplant clinical cases before and after transplant. This supports investigation of daratumumab as a potential therapeutic strategy; however, further research is needed regarding its use for both antibody-mediated rejection and desensitization.
引用
- Kwun J, Matignon M, Manook M, et al. Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use. J Am Soc Nephrol. 2019. PMID: 31227636. doi:10.1681/ASN.2018121254
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。